Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

NCT05478707 on ClinicalTrials.gov · last registry update 2026-10-15

A small phase 2 — 47 participants, against a typical 110. Due to report 30 June 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Microvascular blood volume (MBV). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 5 October 2023 — 3 years so far. dulaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: AdventHealth Translational Research Institute
Sponsor type: Other
Enrollment: 47
Started: 2023-10-05
Primary completion: 2028-06-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Microvascular blood volume (MBV)

Conditions studied

Diabetes Mellitus, Type 1 · Endothelial Dysfunction

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.